Oxaliplatin plus capecitabine combined with concurrent radiotherapy in treatment of locally advanced oesophageal squamous cell cancer
10.3760/cma.j.issn.1004-4221.2009.06.455
- VernacularTitle:奥沙利铂联合希罗达同步放射治疗局限期食管鳞癌疗效观察
- Author:
Caixia WANG
;
Jiandong ZHANG
- Publication Type:Journal Article
- Keywords:
Oesophageal neoplasmas/radiatherapy;
Oesophngeal neoplasmas/chemotherapy;
Chemotherapy,oxaliplatin and capecitabine;
Prognousis
- From:
Chinese Journal of Radiation Oncology
2009;18(6):455-457
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficaey of oxaliplatin plus capecitabine combined with concurrent radiotherapy in treatment of locally advaneed oesophageal squamous cell cancer (OSCC).Methods Between July 2003 and December 2008, 46 patients with locally advanced OSCC were irradiated with a dose of 60-64 Gy in 30-32 fractions. The target area included the primary tumor, the lymph nodes with short axis ≥ 10 ram, and the lymphatic drainage region. Two cycles of concurrent chemotherapy was given during radiotherapy, with the oxaliplatin of 85 mg/m~2 on d_1, d_(21), d_(41) and capecitabine of 850 mg/m~2 on d_(1-14) and d_(21-35), which was followed by two cycles of adjuvant chemotherapy. Results The complete re-sponse rate was 33% (14/46), and partial response rate was 56% (24/46), thus the response rate was 88%. Three patients (7%) had no response and 2 patients (5%) had progression. Obstruction relief rate was 90% ,and pain in the chest and back disappeared in 100% of patients. The 1-,2- and 3-year local con-trol rates and overall survival rates were 72% ,40%, 34% and 80%, 45%, 40%, respectively. Acute ra-diation-induced esophagitis rate was 100%, of which 19% was ≥ grade 3. Leuoopenia occurred in 65% of paients and 23% was ≥ grade 3. 23% of the patients had reduced hemoglobin, and 10% with ≥ grade 3.Hand and foot syndrome rate was 16%, and 4% was ≥grade 3. Conclusions Oxaliplatin plus capecit-abine combined with concurrent radiotherapy may be an effective and well-tolerated regimen in patients with locally advanced oesophageal cancer.
